ClinicalTrials.Veeva

Menu
M

MediSphere Medical Research Center | Evansville, IN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Buprenorphine
ABT-494
Relamorelin
Tanezumab
Ozanimod
Cytisinicline
Astegolimab
Naltrexone Hydrochloride
Lubiprostone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 116 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Other: Placebo
Drug: Ozanimod

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling
RSV Infection
Drug: Placebo
Drug: EDP-938

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the...

Enrolling
Knee Osteoarthritis
Biological: Amniotic Suspension Allograft
Drug: Placebo

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab
Locations recently updated

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Drug: Ozanimod

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting
Osteoarthritis
Drug: RTX-GRT7039
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Migraine
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Enrolling
Vaping Cessation
Smoking Cessation
Drug: Cytisinicline

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Allopurinol
Drug: Tigulixostat

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Pfizer logo
AbbVie logo
Allergan logo
Purdue Pharma logo
Janssen (J&J Innovative Medicine) logo
Shire logo
Achieve Life Sciences logo
Celgene logo
Novartis logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems